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Abstract Myeloma cells specifically localize in the bone 
marrow and rarely circulate in blood. To study whether this 
immobilization could be partially explained by the presence of 
constitutively activated integrins, particularly oi4pi, we used the 
activation reporter HUTS-21 anti-pi mAb. These analyses 
showed that pi integrins on myeloma cells were moderately 
active and could be upregulated similarly to integrins on 
lymphoma or leukemia cells. Myeloma cells were also tested 
for their ability to attach to RGD-containing fibronectin 
fragments, a property of activated (but not resting) a4pi. Two 
cell lines adhered to these fragments and this was inhibited by 
anti-oc5 but not by anti-a4 mAbs. These results show that 
myeloma cells bear low/moderately active (x4pi and support the 
notion that multiple interactions contribute to their localization 
in the bone marrow. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Integrins are a family of surface receptors which mediate 
cell adhesion to multiple ligands in the extracellular matrix 
(ECM), endothelium, or other cell surfaces [1]. Integrins are 
dynamic heterodimeric molecules (aP) which exist in several 
states of activation. Transition from inactive to active forms 
can be modulated by signals from inside the cell as well as by 
external agents [1,2]. Among these agents are the divalent 
cation Mn2+ and some anti-P mAbs which induce a confor-
mational change in the integrin resulting in a high affinity 
receptor [3-5]. Another group of anti-p mAbs such as 
HUTS [6], recognize only activated integrins and are therefore 
useful markers for activation. 
Among B cell malignancies, myeloma cells represent an 
interesting system to study the presence of constitutively acti-
vated integrins. Multiple myeloma is a B cell neoplastic dis-
ease characterized by clonal expansion of the malignant plas-
ma cells within the bone marrow (BM) [7]. In contrast to 
normal plasma cells, myeloma cells localize primarily in the 
BM and rarely circulate in the peripheral blood except at very 
advanced stages of the disease [7]. Previous reports have es-
tablished that activation of oc4pi, the major integrin in most 
normal and malignant B lymphoid cells [8,9], results in inhi-
bition of cell migration on fibronectin (Fn) or vascular cell 
adhesion molecule-1 (VCAM-1), the two ligands for cc4pi 
[10-13]. Such inhibition is likely due to the increased adhesion 
strength induced by the high affinity interactions obtained 
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with activated receptors. It is possible that one of the reasons 
that may contribute to the retention of myeloma cells in the 
BM is the presence of a highly activated form of a4pl. 
oc4pi binds constitutively to the specific sequences CS-1 and 
HI, located in the carboxy-terminal region of Fn [4,12] and 
upon activation with the anti-P 1 mAb TS2/16 or Mn2+, also 
recognizes the RGD sequence in the central cell binding do-
main [14]. Therefore, binding to RGD serves as a criterium 
for evaluating the activation state of ce4pi. In a previous 
study, the adhesion of several myeloma cell lines to Fn was 
inhibited by an anti-a4 mAb as well as by an RGD-contain-
ing peptide [15]. These authors concluded that interaction of 
myeloma cells with Fn involves two different receptors: a4pi 
and an RGD-dependent receptor. Another interpretation 
however, is that cc4pi is present on myeloma cells in the 
activated form and may therefore recognize the RGD se-
quence in Fn. 
In the present report we have tested this hypothesis by: (1) 
studying whether myeloma cell lines attach to Fn fragments 
containing the RGD sequence; (2) analyzing the expression of 
the activation-dependent HUTS-21 epitope on these cells. Our 
results show that a4pi on myeloma cells is not constitutively 
activated and can be regulated similarly to integrins in other B 
cell malignancies such as lymphoma or leukemia. 
2. Materials and methods 
2.1. Fibronectin fragments 
Proteolytic fragments of 80 kDa and 38 kDa were obtained from 
tryptic digests of Fn and purified as previously described [4,14]. The 
80 kDa is derived from the central region of Fn (repeats III4-1//211) 
and contains the RGD cell adhesion site which interacts mainly with 
the a5pl integrin. The 38 kDa fragment is derived from the carboxy-
terminal region of Fn and contains the Hep II domain and the IIICS 
segment; both of these regions contain ligands for a4pT integrin. The 
recombinant fragment FN-III7-10, expanding repeats 1117-10 in Fn 
and therefore containing the RGD sequence, was a gift from Dr. 
Harold Erickson (Duke University Medical Center, Durham, NC, 
USA). 
2.2. Monoclonal antibodies 
Anti-integrin subunit specific antibodies P1E6 (oe2, purified Ab), 
P1B5 (a3, ascitic fluid), P1D6 (cc5, ascitic fluid), and LM609 (aV|33, 
purified Ab) were purchased from Calbiochem-Novabiochem Int., La 
Jolla, CA; mAb HP1/1 (a4, culture supernatant) and Alexl/4 (J31, 
culture supernatant) were obtained from Dr. F. Sanchez-Madrid 
(Hospital de la Princesa, Madrid, Spain); mAb Act-1 (a4fS7, purified 
Ab) was obtained from Dr. Douglas J. Ringler (Leukosite, Cam-
bridge, MA, USA). mAb HUTS-21, specific for an activation epitope 
of (51 was obtained as described [6,13]. 
2.3. Cells and cell cultures 
The human B cell lines IM-9, RPMI 8226, NCI-H929 (derived from 
the bone marrow, peripheral blood or malignant effusion respectively, 
of patients with multiple myeloma), Nalm-6 (pre-B from acute lym-
phoblastic leukemia), WIL2-NS (spherocytic anemia), Daudi and Na-
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malwa (Burkitt's lymphoma) were purchased from the American type 
culture collection (ATCC). Cells were maintained in RPMI 1640 sup-
plemented with 10% fetal bovine serum (ICN Pharmaceuticals, Costa 
Mesa, CA, USA), 2 mM L-glutamine, and 40 ug/ml gentamicin (Gib-
co BRL, Life Technologies S.A., Barcelona, Spain). 
2.4. Flow cytometric analyses 
5X 106 cells were incubated for 30 min at 4°C with 100 u.1 of culture 
supernatants (1:2 dilution) or ascitis (1:100 dilution) containing the 
appropriate mAb. Cells were washed twice with cold PBS—1% BSA 
and resuspended in 100 ul of a 1:30 dilution of fluorescein-conjugated 
F(ab')2 fragments of rabbit antibodies to mouse IgG (Dakopatts, 
Glostrop, Denmark). After 30 min at 4°C cells were washed twice, 
resuspended in 200 pi of PBS and analyzed by flow cytometry on an 
EPICS-CS (Coulter Cientifica, Mostoles, Spain). Analysis of the ex-
pression of the HUTS-21 activation epitope was done in the presence 
of Ca2 ++Mg2 +, or Mn2+ divalent cations exactly as described [6,13]. 
2.5. Cell attachment assays 
These assays were performed as reported [4,12,14] using flat bottom 
high binding 96-well microtiter plates (Costar Co., Cambridge, MA). 
Assays were carried out for 2 h at 37°C, attached cells were stained 
with 0.1% toluidine blue and quantitated by reading the absorbance at 
620 nm on a Multiskan Bichromatic plate reader (Labsystems, Hel-
sinki, Finland), and visually on an inverted microscope (Nikon Dia-
phot, Japan). For inhibition experiments with anti-integrin mAbs, 
cells were incubated in a total volume of 400 pi, with appropriate 
supernatant (1:5 dilution) or ascitic fluid (1:100 dilution) for 30 min 
at room temperature; the cell suspension was then diluted to 5X 105 
cells/ml and 100 pi was added to each substrate-coated well. 
3. Results and discussion 
We first analyzed the expression of relevant integrin sub-
units on B cell lines derived from different pathologies, 
namely multiple myeloma, Burkitt lymphoma and leukemia. 
As shown in Table 1, all cell lines studied expressed moderate 
to high levels of a4 which was present in both forms, o:4pi or/ 
and a4P7. The expression of a5, another Fn receptor, was 
either negative or very low, except for the myeloma cell line 
NCI-H929 which showed similar levels as oc4, and for the 
leukemia-derived Nalm-6 cells (Table 1). This pattern is in 
agreement with the reported major role of oc4 integrin as a 
Fn and VCAM-1 receptor in B cells [9,12]. 
To determine whether oc4pi integrin was present in the 
activated form and thus contributed to the selective retention 
of myeloma cells in the bone marrow, we performed two types 
of experiments: (1) we analyzed the expression of the HUTS-
21 epitope on the pi subunit; (2) we tested the ability of these 
cells to attach to Fn fragments containing the RGD site. 
The HUTS-21 mAb recognizes an epitope in the pi subunit 
which is expressed upon integrin activation. Therefore, con-
stitutive expression of this epitope would be an indication of 
the presence of an activated pi integrin. As shown in Table 2, 
with the exception of IM-9 cells, at 37°C all cell lines showed 
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Fig. 1. Adhesion of human B cell lines to the 80 kDa and FN-III7-
10 Fn fragments. Cells (6x 104) were added to wells coated with the 
indicated concentrations of 80 kDa or FN-III7-10 fragments. After 
2 h at 37°C, attached cells were quantitated as described in Section 
2. Values are the means of at least three different experiments. 
low/moderate basal expression of HUTS-21 epitope under 
resting conditions (Mg2+ and Ca2+) compared to the total 
amount of pi detected by Alexl/4 mAb, with higher levels 
for WIL2-NS (36.2%) and RPMI 8226 (24.5%) cells. In the 
presence of Mn2+, expression of HUTS-21 increased in all cell 
lines in different proportions with maximal ratios for NCI-
H929 (9.1 to 40.7%) and Nalm-6 (15.7 to 46.2%) cells. Inter-
estingly, these two cell lines were the only ones that expressed 
significant amounts of oc5 integrin (Table 1). In conclusion, pi 
integrins on the myeloma cell lines studied displayed a similar 
pattern of activation as that shown by cell lines derived from 
lymphoma, leukemia or anemia. 
The preceding results referred to all pi integrins present on 
these cells. To specifically determine the activation form of 
oc4pi, we took advantage of the ability of activated (but not 
resting) a4pi to recognize the RGD sequence in Fn [14]. Two 
previously described Fn fragments containing this sequence 
were used as substrata for cell adhesion: an 80 kDa tryptic 
fragment which comprises repeats III4—iy2H [14], and a re-
combinant fragment comprising repeats 1117-10 [16]. Another 
tryptic fragment of 38 kDa (IIICS and repeats 11112-14) 
[4,12,14] which contains the cx4pi high affinity ligand CS-1 
was used as positive control. As shown in Fig. 1, the three 
myeloma cell lines tested gave different patterns of adhesion 
to these two fragments. NCI-H929 cells bound very efficiently 
to the 80 kDa fragment and moderately (60% adhesion) to 
FN-III7-10; RPMI 8226 showed moderate adhesion to both 
fragments with maximum levels of 40-50%; and IM-9 cells 
did not bind to any fragment. This different behavior may be 
related to the different body compartment from which these 
cell lines were established (malignant effusion, peripheral 
blood, or BM respectively), which may in turn reflect distinct 
cell maturation stages. The pre-B Nalm-6 cell line also at-
Table 1 
Expression of integrins on the B lymphoid cells studied 
Cells Mean fluorescence intensity 
C a2 a3 a4 a5 a4|37 aV|33 PI 
IM-9 
RPMI 8226 
NCI-H929 
Daudi 
Namalwa 
Nalm-6 
WIL2-NS 
0.17 
0.30 
0.37 
0.27 
0.20 
0.60 
0.20 
0.19 
0.32 
0.37 
0.36 
0.20 
0.58 
0.21 
1.53 
1.35 
0.67 
0.30 
1.45 
0.71 
0.22 
2.42 
0.72 
39.8 
1.43 
3.20 
12.7 
14.4 
0.37 
0.63 
32.5 
0.31 
0.57 
2.98 
0.26 
2.02 
4.19 
2.69 
12.0 
0.35 
1.13 
9.72 
3.27 
2.12 
2.34 
0.38 
0.25 
0.82 
2.02 
4.51 
1.51 
88.2 
2.58 
3.73 
24.0 
9.56 
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Table 2 
Expression of HUTS-21 epitope on B lymphoid cells of different origen 
Cells 
IM-9 
RPMI 8226 
NCI-H929 
Daudi 
Namalwa 
Nalm-6 
WIL2-NS 
4°C 
Ca2++Mg2+ 
C 
0.21 
0.24 
0.23 
0.14 
0.44 
0.97 
0.28 
Alexl/4 
5.73 
1.72 
48.3 
2.15 
3.65 
30.1 
0.85 
HUTS-21 
0.55 
0.28 
4.07 
0.44 
0.26 
2.12 
0.44 
Mn2+ 
C 
0.79 
0.24 
0.14 
0.17 
0.26 
0.58 
0.26 
Alexl/4 
5.42 
2.00 
47.0 
1.95 
4.29 
27.0 
0.94 
HUTS-21 
1.20 
0.35 
16.1 
0.69 
0.43 
9.74 
0.53 
37°C 
Ca2++Mg2+ 
C 
0.18 
0.28 
0.16 
0.16 
0.28 
0.91 
0.29 
Alexl/4 
3.42 
2.28 
47.4 
1.85 
4.26 
30.1 
1.05 
HUTS-21 
0.18 
0.56 
4.33 
0.42 
0.62 
4.74 
0.38 
Mn2+ 
C 
0.18 
0.32 
0.16 
0.16 
0.31 
1.20 
0.26 
Alexl/4 
2.74 
2.35 
47.2 
1.82 
3.94 
26.4 
1.30 
HUTS-21 
0.28 
0.76 
19.2 
0.82 
1.39 
12.2 
0.50 
tached very efficiently to the 80 kDa and FN-III7-10 frag-
ments (Fig. 1), while all other cell lines tested gave negative 
results (not shown). As expected, all cell lines tested attached 
very efficiently to the 38 kDa fragment indicating that a4pi 
integrin on these cells was able to recognize its constitutive 
ligands (results not shown). 
Because the cell lines showing attachment to RGD-contain-
ing fragments express a5 integrin on their surface (Table 1) we 
analyzed whether adhesion to the 80 kDa fragment was medi-
ated by a5(31 or a4(31 integrins or both. For these experi-
ments, cells were pre-incubated with the specific mAbs P1D6 
or HP2/1 prior to the adhesion assay. As shown in Fig. 2, the 
anti-a5 mAb P1D6 completely inhibited adhesion of the three 
cell lines tested, while HP2/1 (anti-oc4) had no significant ef-
fect. These results indicated that adhesion of NCI-H929, 
RPMI 8226, and Nalm-6 cells to the RGD region of Fn 
was mostly mediated by the oc5pi integrin and not by acti-
vated ct4pi. 
The results obtained in the present study therefore indicate 
that a4pi on myeloma cells (and some pre-B cells) is appar-
ently present in an intermediate activation form, unable to 
recognize the RGD sequence under resting conditions but 
susceptible of further activation with Mn2+ . Constitutively 
activated oc4pi was shown to be present on T cells infiltrating 
inflamed synovium in rheumatoid arthritis [17]; likewise, res-
ident B cells acquired an active a4pi integrin upon stimula-
100. 
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6 0 . 
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Fig. 2. Effect of anti-a4 (HP2/1) and anti-a5 (P1D6) mAbs on cell 
adhesion to the 80 kDa Fn fragment. Cells (6X104) were incubated 
for 30 min with HP2/1 or P1D6 mAbs and added to wells coated 
with 80 kDa fragment (76 ug/ml). After 2 h at 37°C, attached cells 
were quantitated. Values are the means of at least two different ex-
periments. 
tion in contrast to peripheral blood B lymphocytes which bore 
an inactive integrin [18]. The myeloma cell system was chosen 
in the present study because of the characteristic retention of 
malignant cells in the BM and their consequent lack of circu-
lation. However, we could not detect significant differences 
with respect to the activation form of oc4pi on myeloma or 
other types of B cell malignancies. This suggests the existence 
of other factors or/and signals in the BM microenvironment 
that contribute to the specific immobilization of malignant 
plasma cells. For example, myeloma cells express other non-
integrin adhesion molecules, such as proteoglycans or selec-
tins, which may mediate adhesive interactions to ligands in the 
BM stroma [8,15]. Additional signals such as interleukin-6, 
which is an autocrine growth factor for myeloma cells and 
inhibits their chemotaxis [19] may also be necessary to main-
tain strong adhesive interactions within the BM. In conclu-
sion, the results reported here show that the state of activation 
of a4pi on myeloma-derived cell lines is low to moderate and 
support the notion that a complex set of interactions between 
malignant plasma cells and BM takes place in multiple mye-
loma. 
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